R

emember January 2014? “Monster,” by Eminem and Rihanna was No. 1 in the U.S., while “Lone Survivor” topped the box office and, for a few days at least, Intercept Pharmaceuticals (ICPT) was a $450 stock.

It’s not anymore, as the chart below illustrates, and it fell about 25 percent further on Thursday after the FDA put out a note that the company’s lead drug, Ocaliva, increased the risk of liver injury and death in some patients. Intercept is down another 14 percent today.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X